AxoGen, Inc. (NASDAQ:AXGN) Shares Sold by Corton Capital Inc.

Corton Capital Inc. trimmed its position in AxoGen, Inc. (NASDAQ:AXGN) by 41.3% during the fourth quarter, Holdings Channel.com reports. The firm owned 15,600 shares of the medical equipment provider’s stock after selling 10,988 shares during the period. Corton Capital Inc.’s holdings in AxoGen were worth $257,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. Barclays PLC grew its position in shares of AxoGen by 119.3% in the third quarter. Barclays PLC now owns 72,036 shares of the medical equipment provider’s stock valued at $1,010,000 after purchasing an additional 39,182 shares during the period. Franklin Resources Inc. boosted its stake in AxoGen by 9.8% in the 3rd quarter. Franklin Resources Inc. now owns 76,048 shares of the medical equipment provider’s stock worth $1,084,000 after buying an additional 6,767 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in AxoGen by 2,912.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 549,000 shares of the medical equipment provider’s stock worth $7,697,000 after buying an additional 530,775 shares during the last quarter. SG Americas Securities LLC grew its holdings in AxoGen by 34.4% in the 4th quarter. SG Americas Securities LLC now owns 21,763 shares of the medical equipment provider’s stock valued at $359,000 after buying an additional 5,576 shares during the period. Finally, R Squared Ltd acquired a new position in shares of AxoGen during the 4th quarter valued at about $30,000. 80.29% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms recently issued reports on AXGN. Cantor Fitzgerald reissued an “overweight” rating and issued a $24.00 target price on shares of AxoGen in a research report on Wednesday, March 5th. Canaccord Genuity Group lifted their price target on shares of AxoGen from $22.00 to $26.00 and gave the company a “buy” rating in a report on Wednesday, February 26th. Finally, Lake Street Capital began coverage on shares of AxoGen in a research note on Monday, March 17th. They set a “buy” rating and a $30.00 price objective for the company. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $22.60.

Insider Transactions at AxoGen

In other news, insider Erick Wayne Devinney sold 15,111 shares of the stock in a transaction dated Wednesday, March 19th. The stock was sold at an average price of $17.50, for a total value of $264,442.50. Following the completion of the sale, the insider now owns 217,762 shares in the company, valued at approximately $3,810,835. This trade represents a 6.49 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Amy Mcbride Wendell sold 5,000 shares of the firm’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $20.02, for a total value of $100,100.00. Following the sale, the director now owns 97,899 shares in the company, valued at approximately $1,959,937.98. The trade was a 4.86 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 7.00% of the company’s stock.

AxoGen Trading Down 0.4 %

NASDAQ AXGN opened at $16.34 on Thursday. The firm has a market capitalization of $744.09 million, a price-to-earnings ratio of -51.07 and a beta of 1.19. The company has a debt-to-equity ratio of 0.67, a quick ratio of 2.47 and a current ratio of 3.74. AxoGen, Inc. has a one year low of $5.65 and a one year high of $21.00. The company’s 50 day moving average price is $17.02 and its 200 day moving average price is $16.31.

About AxoGen

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.